Caris Target Now ™ and Carisome ™ are products of Caris Life Sciences™. For more information please visit our Linkedin page http://linkd.in/LbSPQJ. For more information about the services of the former pathology division of Caris Diagnostics, please visit MiracaLifeSciences.com.
| Website | http://www.carislifesciences.com |
| Revenue | $361 million |
| Employees | 61 (30 on RocketReach) |
| Founded | 1996 |
| Industry | Biotechnology |
| Web Rank | 2 Million |
| Keywords | Molecular Diagnostics, Tumor Profiling, Cancer Diagnostics, Cancer Biomarkers, Precision Oncology, Dna Sequencing, Liquid Biopsy, Genomic Testing, Pharmacogenomics, Biomarker Discovery, Ngs Testing, Cancer Research, Oncology Testing, Personalized Medicine, Diagnostic Testing, Clinical Diagnostics, Molecular Profiling, Pathology Testing, Genetic Testing |
| Competitors | Natera, Tempus Labs, Inc., Guardant Health, Myriad Genetics, Foundation Medicine, Caris Life Sciences, Invitae, Lengo Therapeutics, Freenome, Strata Oncology +45 more (view full list) |
Looking for a particular Caris Diagnostics employee's phone or email?
The Caris Diagnostics annual revenue was $361 million in 2026.
Steve McMindes is the Senior VP of Caris Diagnostics.
30 people are employed at Caris Diagnostics.